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Genomic breakpoints and clinical features 
of MLL-TET1 rearrangement in acute leukemias
Recent rapid developments in new technology such as
whole genome/exome sequencing have revealed that
novel mutations in genes such as DNMT3A, IDH1, IDH2
and TET2 contribute to the main process of leukemogene-
sis in patients with normal karyotype acute myeloid
leukemia (AML).1 Among these genes, TET2, a TET family
gene located on 4q24, is important because of its high fre-
quency of mutations in myeloid neoplasms such as myelo-
proliferative neoplasm (MPN), myelodysplastic syndromes
(MDS), MDS/MPN, and AML.2 In contrast, the TET1 gene,
first discovered in 2002 and located on 10q22, is rarely
reported as a translocation partner for MLL rearrange-
ments in acute leukemias.3,4 Only 10 cases have been
reported with chromosomal translocations
t(10;11)(q22;q23) interchangeable with MLL-TET1
fusions.4-11 There has been little research into the common
features of MLL-TET1 rearrangements. Here we provide
information about molecular and clinical characterization
of MLL-TET1 rearrangements diagnosed in 3 AML
patients. 
Using the long-distance inverse-polymerase chain reac-
tion (LDI-PCR) method, 3 AML patients with MLL-TET1
rearrangements were identified between January 2005 and
December 2011 at the Diagnostic Center of Acute
Leukemia (DCAL) in Frankfurt. All 3 cases were sent to the
DCAL because of positive results for MLL rearrangements
by conventional cytogenetics and fluorescence in situ
hybridization (FISH), but routine analysis did not reveal
the fusion partner of MLL. The 3 patients were from dif-
ferent institutions in Korea, Germany and France. Case 2
of this study was briefly mentioned (for rearrangement
type) in a previous study.12
The results of clinical parameters, cytogenetic studies,
FISH, reverse transcriptase-PCR and LDI-PCR analyses on
bone marrow specimens at the time of diagnosis for 3 new
AML cases are shown in Table 1. Including 3 new cases,
this research analyzes a total of the 13 acute leukemia
cases of t(10;11)(q22;q23) known so far, detected in 11
AML and 2 ALL patients. We summarized the published
data to evaluate patients’ characteristics (Table 2).4-11 A
molecular characterization at the genomic or transcript
level was performed only for a subset of patients. Eight of
11 AML patients (72.7%) were classified as FAB-M4/M5
subtypes; 7 men and 5 women with a median age of 38.0
years (range 1 month to 67 years). For one patient, no clin-
ical data could be retrieved.11 Of 9 patients with available
chromosome study results, 3 had a sole chromosomal
abnormality of t(10;11), and the remaining 6 had accom-
panying additional chromosomal abnormalities. MLL-
TET1 rearrangement was confirmed in 8 of 13 cases and
chromosomal breakpoints were also identified in these
cases (Tables 1 and 2). All genomic breakpoints within the
TET1 gene were identified in an approximately 17 kb
genomic region flanked by TET1 exons 8 and 12 (Figure 1).
But most characterized breakpoints (5 of 7 cases) were
mapped to intron 8. Because only 7 of the 13 patients had
available clinical outcomes, a sufficient amount of data is
not available. Nevertheless, the results showed that 6
patients had complete remission. Five patients, including
one who did not reach complete remission, died at an
average of 14.5 months after initial diagnosis, showing lit-
tle difference with the known poor prognosis of patients
with MLL rearrangements. 
TET1 encodes a protein of 2136 amino acids with a
molecular mass of 235.3 kDa. TET1 contains a CXXC
domain at position 583–624, a coiled-coil region near the
C-terminus (position 2,062–2,091), and three candidate
bipartite nuclear localization signals.4,7 Lorsbach et al.7
found that the expression of TET1 within the hematolym-
phoid system was limited to spleen, with no detectable
expression in bone marrow or peripheral blood leuko-
cytes. MLL-TET1 fusion proteins are predicted to have a
molecular mass of 204.4 kDa and to retain the AT hooks,
subnuclear localization domains, and CXXC motif of MLL,
as well as the coiled-coil region and the most C-terminal
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Figure 1. Schematic representation of TET1 intron breakpoints on
4 reported cases and 3 new cases using genomic analyses.
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Table 1. Characterization of 3 new acute myeloid leukemia cases with MLL-TET1 gene rearrangement.
Case 1 Case 2 Case 3
Gender/Age M/39 F/60 M/18
Country Korea Germany France
Diagnosis AML (FAB M4) AML (FAB M4) AML (therapy-related : VP16 for 
Ewing sarcoma)
Peripheral blood finding at diagnosis Hb: 9.6 g/dL Hb: 9.5 g/dL Hb: 5.4 g/dL
PLT: 52×109/L PLT: 55×109/L PLT: 12×109/L
WBC: 9.1×109/L WBC: 89.5×109/L WBC: 12.9×109/L
Blast counts in PB and BM 73% and 40% BM: 90% 1% and 21%
BM interpretation with 85% cellular marrow. Bone marrow hypercellularity Erythroid and granulocytic dysplasia 
cellularity Erythroid dysplasia (binucleation, with myelo-monocytic 
nuclear budding, intercytoplasmic blast population.
bridge, megaloblastic changes).
Immunophenotype MPO+, CD34+, CD117+, TdT- NA MPO+, butyrates +, CD34+, CD117-, 
CD33+, CD13+
Chromosome study 46,XY,t(10;11)(q22;q23)[4]/47,idem,+21[16] 46,XX,t(10;11)(q22;q23)[21] 46,XY,t(10;11)(q22;q23)[2]/46,idem, 
del(6)(p21)[18]
MLL FISH results nuc ish (MLLx2)(5’MLL sep 3’MLLx1) nuc ish (MLLx2) nuc ish (MLLx2)(5’MLL sep
[495/500] (5’MLL sep 3’MLLx1) [80/100] 3’MLLx1)[95/100]
Method for MLL/TET1 LDI-PCR, RT-PCR LDI PCR LDI PCR
rearrangement
Breakpoints (MLL/TET1) MLL intron 8/ TET1 intron 8 MLL intron 9/ TET1 intron 8 MLL intron 10/ TET1 intron 10
Clinical outcome NA Reached CR. Bone marrow Surviving 20 months after diagnosis.
transplanted. Relapsed 
18 months after diagnosis and 
died 21 months after diagnosis.
M: male; F: female; FAB: French-American-British classification; PB: peripheral blood; BM: bone marrow; AML: acute myeloid leukemia; NA: not available; FISH: fluorescence in situ hybridization; RT-
PCR: reverse transcription-polymerase chain reaction; LDI-PCR: long-distance inverse PCR; CR: complete remission. Hb: hemoglobin; PLT: platelets; WBC: white blood cell count.
Table 2. Summary of previously reported t(10;11) (q22;q23) cases.
Patient Gender/Diagnosis Chromosomal study Method for Genomic cDNA Clinical Bone References
N. Age (FAB) MLL/TET1 DNA breakpoint outcome marrow
rearrangement breakpoint dysplasia
1 NA AML t(10;11)(q22;q23) NA NA NA NA NA Thirman 
(M5) et al.11
2 M/46 AML 46,XY,t(10;11)(q22;q23), NA NA NA Achieved CR, NA Harrison
(M5a) add(13)(p11)/46,XY,t EFS 6.7 mo, et al.10
(10;11),der(6)t(6;?9) Survival 6.7 mo
(p22;?q21)
3 F/30 AML 46,XX,-10,der(11)t(10;11) NA NA NA Achieved CR, NA Harrison
(M5b) (q22;q23),add(22))q13),+r EFS 6.4 mo, Survival 10.6 mo et al.10
4 F/35 AML 51,XX,+8,t(10;11)(q22;q23), FISH NA NA Not achieved CR, survival Mild Aventin 
(M4) +13,+18,+18,+20[10]/46,XX[5] 8 mo, died of infection dyshemopoiesis et al.9
5 M/1mo AML 46,XY,del(5)(q15),t(10;11) NA NA NA NA NA Kim
(M4) (q22;q23)[19] /46,XY[1], et al.8
6 M/67 AML 46,XY, t(10;11)(q22;q23) Southern blot, MLL MLL exon Achieved CR, EFS 24 mo, Trilineage Ono
(M2) RT-PCR cDNA intron 8/TET1 exon 10 survival 26 mo, died dysplasia et al.4
panhandle PCR 9/TET1 MLL exon of infection
intron 8 9/TET1 exon 9
7 M/8 AML 46,XY, t(10;11)(q22;q23) RT-PCR, MLL intron MLL exon CR for 24 months + NA Lorsbach
(M4) LDI-PCR 6/TET1 intron 8 9/TET1 exon 9 et al.7
8 M/54 AML NA RT-PCR NA MLL exon NA NA Shih 
(M2) 8/TET1 (NA) et al.6
9 F/57 ALL NA RT-PCR, MLL intron MLL exon NA NA Burmeister
LDI-PCR 10/TET1 9/TET1 exon 9 et al.5
intron 8
10 F/67 ALL NA RT-PCR, MLL intron MLL exon NA NA Burmeister
LDI-PCR 7/TET1 intron 11 7/TET1 exon 12 et al.5
N: number; M: male; F: female; mo: month; FAB: French-American-British classification; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; NA: not available; FISH: fluorescence in situ
hybridization; RT-PCR: reverse transcription-polymerase chain reaction; LDI-PCR: long-distance inverse PCR; EFS: event-free survival; CR: complete remission.
nuclear localization domain of TET1.7 The role of the
MLL-TET1 fusion gene in leukemogenesis is unknown, as
is the physiological role of TET1.5 Further clinical and
molecular research on acute leukemias with MLL-TET1
rearrangements is necessary, including functional study of
the MLL-TET1 fusion gene, to define the role of such rare
MLL-related fusion genes in leukemogenesis.
There is a need to collect and report recurrent genomic
or cytogenetic aberrations since such data on leukemia
patients with particular genetic abnormalities improve our
current understanding of genetic and clinical features in
acute leukemias. Further research on the biological and
prognostic effects of MLL-TET1 rearrangements using ani-
mal models or human leukemia samples is also required in
the near future.
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